Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A dystonia that is combined with another movement disorder (e.g., myoclonus, parkinsonism).
No HPO annotations are available for this condition.
X-linked dystonia-parkinsonism (XDP) or lubag afflicts primarily adult Filipino men and, rarely, women. The male-to-female ratio is 99:1. The mean age of onset in men is 39 years, with a range of 12 to 64 years. The mean age of onset in women is 52 years, with a range of 26 to 75 years . The time from onset of dystonia to generalization ranges from one to 23 years, with a mean of 3.8 years. The clinical course in men with XDP is highly variable. Although the presenting finding was traditionally thought to be dystonia in most cases , a longitudinal follow up of asymptomatic or early symptomatic individuals with genetically confirmed XDP revealed that the initial presenting sign is almost universally parkinsonism .
The diagnosis of X-linked dystonia-parkinsonism (XDP) should be suspected in an individual with the following clinical findings, neuroimaging results, and neurophysiologic test results.
Clinical findings
Dystonia of varying severity, ranging from focal to generalized typically starting in early adulthood
Parkinsonism
No approved treatments are currently available for combined dystonia. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with X-linked dystonia-parkinsonism (XDP) syndrome, the following evaluations are recommended if they have not already been completed:
Neurologic examination
Presymptomatic males known to have the disease-associated haplotype may need yearly clinical evaluations after age 30 years to identify the onset of symptoms in order to institute appropriate therapy as early as possible. Once an individual is symptomatic, biannual follow ups are recommended in order to adjust medications to assure best management of dystonia and/or parkinsonism. Periodic swallowing evaluation, especially in those with subjective dysphagia, is appropriate.
Source: GeneReviews — "X-Linked Dystonia-Parkinsonism"
1 clinical trial registered. Interventions under study include other interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
16 publications have been identified in PubMed for combined dystonia. Research spans Case Report / Case Series (50%), Review / Meta-Analysis (13%), and Basic Science / Preclinical (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 8 | 50% |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 10:49 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about combined dystonia
Source: GeneReviews — "X-Linked Dystonia-Parkinsonism"
Family history consistent with X-linked inheritance
Maternal ancestral roots from the Panay Islands in the Philippines where XDP originated as a genetic founder effect. All known affected individuals to date are of Filipino descent.
Source: GeneReviews — "X-Linked Dystonia-Parkinsonism"
See Dystonia Overview. Individuals with X-linked dystonia-parkinsonism (XDP) with tremor can be misdiagnosed as having Parkinson disease or essential tremor, especially in the early stages in which dystonia may be absent or subtle. Individuals with XDP with all the cardinal features of parkinsonism, asymmetric findings, and levodopa responsiveness are often diagnosed as having Parkinson disease or Parkinson-plus syndrome.
Source: GeneReviews — "X-Linked Dystonia-Parkinsonism"
Biomarker and diagnostic research for combined dystonia has been reported in the published literature.
Assessment of speech
Assessment of swallowing
Nutritional assessment
Surface electromyography study
Consultation with a clinical geneticist and/or genetic counselor
Treatment of Manifestations
Anticholinergic agents and benzodiazepines. In the early stages of the disease when dystonia is focal or segmental in distribution, individuals may respond significantly to anti-dystonia medications, particularly to anticholinergic agents and benzodiazepines.
The two most commonly prescribed anticholinergic drugs are trihexyphenidyl (Artane) and biperiden (Akineton). Trihexyphenidyl appears to have a more consistent and beneficial effect than biperiden, especially in the moderate-to-advanced stages.
The benzodiazepine associated with the best response is clonazepam.
Even greater improvement in dystonia is noted when anticholinergic drugs are combined with clonazepam.
Source: GeneReviews — "X-Linked Dystonia-Parkinsonism"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "X-Linked Dystonia-Parkinsonism"
1 trial found
Research summaries |
2 |
13% |
Laboratory research | 2 | 13% |
Testing and diagnosis research | 1 | 6% |
Clinical study results | 1 | 6% |
Disease patterns and progression | 1 | 6% |
New treatment approaches | 1 | 6% |
Li XT (2026). [PMID: 42158583](https://pubmed.ncbi.nlm.nih.gov/42158583/). *Front Hum Neurosci*. [Case Report / Case Series]
Fontanesi D (2026). [PMID: 40827393](https://pubmed.ncbi.nlm.nih.gov/40827393/). *Movement disorders clinical practice*. [Case Report / Case Series]
Saparov A (2026). [PMID: 41623120](https://pubmed.ncbi.nlm.nih.gov/41623120/). *Annals of neurology*. [Diagnostic / Biomarker]
Ottaviani D (2026). [PMID: 41978253](https://pubmed.ncbi.nlm.nih.gov/41978253/). *Am J Med Genet A*. [Case Report / Case Series]
Hect JL (2026). [PMID: 42024243](https://pubmed.ncbi.nlm.nih.gov/42024243/). *Childs Nerv Syst*. [Case Report / Case Series]
Idrissi S (2025). [PMID: 40246732](https://pubmed.ncbi.nlm.nih.gov/40246732/). *Journal of neural transmission (Vienna, Austria : 1996)*. [Epidemiology / Natural History]
Romito LM (2025). [PMID: 39446029](https://pubmed.ncbi.nlm.nih.gov/39446029/). *Movement disorders clinical practice*. [Case Report / Case Series]
Magistrelli L (2025). [PMID: 39450570](https://pubmed.ncbi.nlm.nih.gov/39450570/). *Movement disorders clinical practice*. [Case Report / Case Series]
Calakos N (2025). [PMID: 39467044](https://pubmed.ncbi.nlm.nih.gov/39467044/). *Mov Disord*. [Review / Meta-Analysis]
de Souza JCC (2024). [PMID: 38922176](https://pubmed.ncbi.nlm.nih.gov/38922176/). *Toxins (Basel)*. [Clinical Trial Publication]